

Safety reporting in CTIS

Webinar for SMEs and Academia on the Clinical Trial Regulation (Regulation (EU) No 536/2014) and the Clinical Trials Information System (CTIS)



© European Medicines Agency, 2021

Reproduction and/or distribution of the content of these training materials for non-commercial or commercial purposes is authorised, provided the European Medicines Agency is acknowledged as the source of the materials.

The European Medicines Agency developed this training material to enhance public access to information on the Clinical Trial Information System (CTIS). This material describes a preliminary version of CTIS and may therefore not entirely describe the system as it is at the time of use of this material. The Agency does not warrant or accept any liability in relation to the use (in part or in whole) or the interpretation of the information contained in this training material by third parties.

Table of contents



- 1. Future changes to clinical trial safety reporting
- 2. Submission of Annual Safety Reports
- 3. EU Network cooperation



Future changes to clinical trial safety reporting

Changes to clinical trial safety reporting - overview



- CTR demands electronic submission of SUSARs and ASRs
- SUSARs will be submitted to the EudraVigilance database (EV CTM)
- ASRs will be submitted via CTIS
- COM will adopt implementing regulation
- saMS will assess safety relevant data substance based
- Communication between MSs and with sponsors will be via CTIS (ASR, ad hoc assessment, corrective measures)
- IT support not yet fully developed, will be further developed post go live
- CTFG will develop and adapt internal guidance

Requirements for the transition period



SUSAR:

- SUSARs to EV unless the NCA requires direct reporting
- Reporting obligations as of CT-3 to investigators and ECs according to national legislations in MSs with CTs within Directive

ASR:

- With first trial for a substance under the CTR: ASR to CTIS
- Informative cover letter essential: name all MSCs for ongoing CTs in EU/EEA within Directive and CTR.
- Obligation as of CT-3 to investigators (new safety data or change in B/R) and ECs according to national legislations in MSs with ongoing CTs within Directive remains




Submission of Annual Safety Reports

Initiate ASR submission (ASR submitter)




Clinical trials There is no save button; make sure you have all documents available before you start



1. Enter Sponsor Information

Sponsor information






2. Enter Clinical Trial Details

▲ Step 2

Clinical Trial Detail






3. Enter ASR reporting period details

Step 3

ASR Reporting Period details






4. Upload documents and submit

Step 4









Find the RFIs according to type in the RFI tab






Respond to the RFI and attach missing/supporting documents





End of assessment information available for the sponsor







EU Network cooperation

Legal Framework: Implementing Regulation



Article 44.2 of the CTR allows COM to set up and modify rules for cooperation in the assessment of SUSARs and ASRs. New concepts were created:

- Safety assessing Member state (saMS)
- saMS is in charge of the surveillance for a substance (all SUSARs and ASR for all trials)
- saMS develops general recommendations in relation to safety concerns
- RMS/MSC implement them if applicable to their trials via corrective measures
- Cooperation between saMS, RMS and MSCs in CTs using the same active substance
- IT support not yet fully developed
- CTFG develops internal guidance for assessment and work around to overcome missing IT support



Any questions?

Further information

emaevents@diaglobal.org (CTIS sponsor Master Trainer programme)
CT.Sponsortraining@ema.europa.eu (general queries on other (sponsor) training)

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact



Legal Framework: Regulation (EU) No 536/2014



Article 42: Reporting of suspected unexpected serious adverse reactions by the sponsor to the Agency (abbreviated and adapted wording)

- The sponsor shall report electronically all SUSARs to IMPs occurring in that clinical trial, irrespective of location of occurrence (in the Union or in a third country) regardless of pharmaceutical form and strength or indication investigated, even after the EOT.
- 2. The reporting period for SUSARs if **fatal or life-threatening** as soon as possible not later than **7 days**, if **non-fatal or non-life-threatening** not later than **15 days** after becoming aware; if initially non-fatal or non life threatening turning into fatal or life-threatening, as soon as possible not later than 7 days after this change. Where necessary submit an initial incomplete report followed up by a complete report.
- 3. Where a sponsor does not have the possibility to report to EV and with MS agreement it may report to the MS where the SUSAR occurred. That Member State shall report to 18 EV.

Legal Framework: Regulation (EU) No 536/2014



Article 43: Annual reporting by the sponsor to the Agency

- 1. Regarding investigational medicinal products other than placebo, the sponsor shall submit **annually** through the database referred to in Article 40(1) to the Agency a **report on the safety of each investigational medicinal product** used in a clinical trial for which it is the sponsor.
- 2. In the case of a clinical trial involving the use of **more than one investigational medicinal product**, the sponsor may, if provided for in the protocol, submit a **single** safety **report** on all investigational medicinal products used in that clinical trial.
- 3. The annual report referred to in paragraph 1 shall only contain **aggregate and anonymised data**.
- 4. The obligation referred to in paragraph 1 starts with the first authorisation of a clinical trial in accordance with this Regulation. It **ends with the end of the last clinical trial** conducted by the sponsor with the investigational medicinal product.

Legal Framework: Regulation (EU) No 536/2014



Article 44: **Assessment by Member States**

- 1. The Agency shall, by electronic means, forward to the Member States concerned the information reported in accordance with Article 42 and 43.
- 2. Member States shall cooperate in assessing the information reported in accordance with Articles 42 and 43. The Commission may, by means of implementing acts, set up and modify the rules on such cooperation. Those implementing acts shall be adopted in accordance with the examination procedure referred to in Article 88(2).
- 3. The responsible ethics committee shall be involved in the assessment of the information referred to in paragraphs 1 and 2, if it has been provided for in the law of the Member State concerned.

CTR Questions & Answers (Chapter 7 safety reporting)

Reference Safety information (RSI)

Reporting of AEs/ARs: Provide worldwide unique case identification number

Annual Safety Reports: Provide patient numbers in SAE tables

Safety Issues of AxMPs: authorised AxMPs to EVPM, non-authorised AxMPs to EVCTM

Safety during Transition Period of Clinical Trials Regulation (EU) No 536/2014 Implementation:

With first trial for a substance under the CTR: ASR to CTIS (name all MSCs for ongoing CTs in EU/EEA within Directive and CTR). Obligation as of CT-3 to investigators (new safety data or change in B/R) and ECs according to national legislations in MSs with ongoing CTs within Directive remains.

SUSARs to EV unless the NCA requires direct reporting. Reporting obligations as of CT-3 to investigators and ECs according to national legislations in MSs with CTs within Directive https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-10/regulation5362014 ga en.pdf 21